Non-Alcoholic Fatty Liver Disease (NAFLD) is currently the most common cause of chronic
liver disease worldwide, and its prevalence is increasing globally. NAFLD is a multifaceted …

Obesity is a critical risk factor for the development of metabolic diseases, and its prevalence
is increasing worldwide. Stem cell‐based therapies have become a promising tool for …

Nuclear magnetic resonance (NMR)-based plasma fatty acids are objective biomarkers of
many diseases. Herein, we aim to explore the associations of NMR-based plasma fatty acids …

Acetyl-CoA synthetase short-chain family member 1 (ACSS1) uses acetate to generate
mitochondrial acetyl-CoA and is regulated by deacetylation by sirtuin 3. We generated an …

Gut microbiota plays an essential role in the progression of nonalcoholic fatty liver disease
(NAFLD), making the gut-liver axis a potential therapeutic strategy. Bacteroides genus, the …

Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease, and is
related to fatal and non-fatal liver, metabolic, and cardiovascular complications. Its non …

Metabolic dysfunction‐associated steatotic liver disease (MASLD) is a growing cause of
morbidity with limited treatment options. Thus, accurate in vitro systems to test new therapies …

Dysbiosis of gut microbiota and its derived metabolites has been linked to the occurrence
and development of nonalcoholic fatty liver disease. Our previous study has demonstrated …

Red rice bran extract (RRBE) is rich in phytonutrients and has been shown to have anti-
diabetic, anti-inflammatory, and antioxidant properties. However, its anti-hepatic steatosis …

Objective Alterations in the hepatic lipidome are a crucial factor involved in the
pathophysiology of nonalcoholic fatty liver disease (NAFLD). The aim of this study was to …